Olema insiders sell millions amid analyst upgrades now
Tap title to read story
United States — Olema Pharmaceuticals executives sold shares between December 19 and December 23, 2025, according to Securities and Exchange Commission filings. Chief Medical Officer Naseem Zojwalla sold $7.5 million of common stock and exercised options; Director Ian T. Clark sold $7.87 million and exercised options; David Myles sold about $1.55 million and reported ownership changes. The moves coincided with analyst price‑target increases following interim results from Roche’s Phase 3 lidERA trial and with market volatility in OLMA shares. All transactions were disclosed via SEC filings and reported by financial news services. Based on 6 articles reviewed and supporting research.
More context
Timeline
- 1. Prior to December 2025: Olema develops OP-1250 (SERD/CERAN) as lead candidate in women's cancers.
- 2. Mid-December 2025: Roche presents interim data from its Phase 3 lidERA trial, increasing industry focus on SERD class.
- 3. Following the presentation: Analysts (H.C. Wainwright, Goldman Sachs, Jefferies) raise price targets for Olema and peers.
- 4. December 19, 2025: SEC filings show David Myles and Ian T. Clark sold shares and exercised options.
- 5. December 19–23, 2025: CMO Naseem Zojwalla sold shares and exercised options; financial outlets report market reactions.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
